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Abstract
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Neurotensin is an endogenous neuropeptide closely associated with the mesolimbic dopaminergic
system and shown to possess antipsychotic-like effects. In particular, acute neurotensin receptor
activation can inhibit conditioned avoidance response (CAR), attenuate phencyclidine (PCP)induced prepulse inhibition (PPI) disruptions, and reverse PCP-induced hyperlocomotion.
However, few studies have examined the long term effects of repeated neurotensin receptor
activation and results are inconsistent. Since clinical administration of antipsychotic therapy often
requires a prolonged treatment schedule, here we assessed the effects of repeated activation of
neurotensin receptors using an NTS1 receptor selective agonist, PD149163, in 3 behavioral tests
of antipsychotic activity. We also investigated whether reactivity to the atypical antipsychotic
clozapine was altered following prior PD149163 treatment. Using both normal and prenatally
immune activated rats generated through maternal immune activation with
polyinosinic:polycytidilic acid, we tested PD149163 in CAR, PCP (1.5 mg/kg)-induced PPI
disruption, and PCP (3.2 mg/kg)-induced hyperlocomotion. For each paradigm, rats were first
repeatedly tested with vehicle or PD149163 (1.0, 4.0, 8.0 mg/kg, sc) along with vehicle or PCP for
PPI and hyperlocomotion tests, then challenged with PD149163 after 2 drug-free days. All rats
were then challenged with clozapine (5.0 mg/kg, sc). During the repeated test period, PD149163
exhibited antipsychotic-like effects in all three models. On the PD149163 challenge day, prior
drug treatment only caused a tolerance effect in CAR. This tolerance in CAR was transferrable to
clozapine, as it enhanced clozapine tolerance in the same group of animals. Although no tolerance
effect was seen in the PD149163 challenge for the PCP-induced hyperlocomotion test, the
clozapine challenge showed increased sensitivity in groups previously exposed to repeated
PD149163 treatment. Our findings suggest repeated exposure to NTS1 receptor agonists can
induce a dose-dependent tolerance and cross-tolerance to clozapine to some of its behavioral
effects but not others.

NIH-PA Author Manuscript

*

Corresponding author: Ming Li, PhD, Associate Professor, Department of Psychology, University of Nebraska-Lincoln, 238 Burnett
Hall, Lincoln, NE 68588-0308, USA. Telephone: 402-472-3144. mli2@unl.edu.
The authors report no conflicts of interest.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Chou et al.

Page 2

Keywords

NIH-PA Author Manuscript

Neurotensin; Clozapine; Conditioned avoidance response; Phencyclidine; Locomotor activity;
Prepulse inhibition; Maternal immune activation; Sensitization; Tolerance

INTRODUCTION

NIH-PA Author Manuscript
NIH-PA Author Manuscript

Neurotensin (NT) is an endogenous 13-amino acid neuropeptide ubiquitous in the central
nervous system (CNS) (Carraway and Leeman, 1973, 1975). The neurotransmitter and its
two main receptor subtypes, the NTS1 and NTS2 G protein-coupled receptors, are especially
highly distributed in the hypothalamus, amygdala, and the nucleus accumbens, and are
associated with the mesolimbic dopaminergic system (Boudin et al, 1996; Chalon et al,
1993; Cooper et al, 1981; Mazella et al, 1996; Tanaka et al, 1990; Vita et al, 1996). Within
the CNS, NT is involved in an array of processes, including the activation of intracellular
signaling pathways (Hermans et al, 1993), modulation of cytokine expression (Wang et al,
2006), stress-induced analgesia (Dobner et al, 2001; Gully et al, 1993, 1997; Maeno et al,
2004; Pettibone et al, 2002; Remaury et al, 2002), and the sensitization to psychostimulant
drugs (Betancur et al, 1998; Costa et al, 2001; Horger et al, 1994; Panayi et al, 2002, 2005).
NT has also been implicated in both the etiology and treatment of schizophrenia. Clinical
studies have shown that some schizophrenic patients have reduced levels of NT in the
cerebrospinal fluid, and treatment with antipsychotic drugs (APDs) is able to restore NT
levels (Breslin et al, 1994; Garver et al, 1991; Lindström et al, n.d.; Nemeroff et al, 1989;
Sharma et al, 1997; Widerlöv et al, 1982). In addition, NT signaling seems to play a crucial
role in mediating the central actions of available APDs. Treatment of patients with APDs
has been shown to increase NT levels in specific brain regions (Govoni et al, 1980; Kinkead
et al, 2000), and both NT- and NT receptor-null mouse models have demonstrated defects in
APD response compared to controls (Kinkead et al, 2005). Numerous studies have further
examined the possibility of NT as an exogenous atypical APD (Boules et al, 2001; Feifel et
al, 1997, 1999; Hertel et al, 2002; Li et al, 2010b; Shilling and Feifel, 2008; Shilling et al,
2003), a classification generally given to therapeutics effective in alleviating psychotic
symptoms without causing severe extrapyramidal side effects (Wadenberg and Hicks, 1999).
Receptor stimulations with NT or agonists have produced APD-like effects in models with
high predictive validity of efficacy (Gleason and Shannon, 1997; Natesan et al, 2006;
Wadenberg, 2010), including the attenuation of phencyclidine (PCP) and d-amphetamine
induced hyperactivity (Boules et al, 2001; Li et al, 2010b), disruptions in the conditioned
avoidance response (CAR) (Hertel et al, 2001), and the reversal of prepulse inhibition (PPI)
deficits induced by d-amphetamine (Shilling et al, 2003), as well as dopamine, serotonin,
and α-1 adrenoreceptor agonists (Feifel et al, 1999, 2003; Shilling et al, 2003, 2004).
PD149163 (PD) is an NTS1 receptor-selective agonist that crosses the blood-brain barrier
and is shown to have APD-like properties in animal studies (Petrie et al, 2004). Acute
systemic injections of PD exhibit diminished CAR without generating catalepsy (Holly et al,
2011), and improve the reduction of PPI in Brattleboro rats and by amphetamine,
dizocilpine, and serotonin 2A and α-1 adrenoreceptor agonists (Feifel et al, 2009). However,
as most APD regimens require a repeated and chronic administration, it is clinically relevant
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to investigate the chronic effects of PD. Previous research using the NT analogue NT69L
suggests the emergence of a tolerance phenomenon in both CAR and amphetamine-induced
hyperactivity (Feifel et al, 2007; Hertel et al, 2001, 2002; Norman et al, 2008a), while more
recent studies of repeated PD exposure seem to contradict the tolerance effect using
amphetamine-induced hyperactivity and Brattleboro PPI models (Feifel et al, 2008). These
discrepancies may be due to the choice of dosage, as earlier work has observed dosedependent effects of NT infusion (Feifel et al, 1997), or perhaps the chosen time points. In
order to resolve these discrepancies, in the present study, we assessed the long-term repeated
effects of PD in three distinct animal tests of antipsychotic activity: the repeated CAR, PCPinduced hyperlocomotion, and PCP-induced PPI models. For each model, we employed a
behavioral paradigm similar to those used for the study of psychomotor sensitization
(Robinson et al, 1998; Stewart and Badiani, 1993). The procedure involves inducing
changes in behavioral sensitivity to APDs over days through repeated drug administration,
then assessing the expression of the long term behavioral alterations in a subsequent
challenge test. We have shown that in the CAR test, the typical APD haloperidol and the
atypical APD olanzapine (OLZ) both cause long term sensitization effects (Li et al, 2007,
2010a; Mead and Li, 2010; Qiao et al, 2013b; Qin et al, 2013; Sun et al, 2009; Zhang and
Li, 2012; Zhao et al, 2012), while clozapine (CLZ) induces a tolerance effect during the
challenge trial following repeated drug exposure (Feng et al, 2013; Li et al, 2011; Qiao et al,
2013a, 2013b). Furthermore, we have recently established that the long term modulation of
behavioral sensitivity induced by one APD can affect the behavioral sensitivity to another
APD not previously exposed to the animal (Qin et al, 2013). In light of these findings, we
also examined whether prior PD treatment would alter drug sensitivity to CLZ.

NIH-PA Author Manuscript

MATERIALS AND METHODS
Animals

NIH-PA Author Manuscript

Subject rats were mixed groups of female Sprague-Dawley adult offspring (> P75 days old)
of pregnant dams from Charles River (Portage, MI; gestation day [G] 6 on delivery date)
that were injected with either the immunostimulant polyinosinic:polycytidilic acid (PolyI:C,
4.0 mg/kg, intravenous [iv]) (Sigma-Aldrich, St. Louis, MO) or vehicle (VEH, 0.9% saline).
Previous work suggests that maternal immune activation (MIA) with gestational PolyI:C
treatment reproduces many behavioral abnormalities resembling symptoms of schizophrenia
(Piontkewitz et al, 2009; Zuckerman and Weiner, 2005). Thus far only a few studies have
investigated the effects of APDs using prenatally immune activated animals. We postulated
that we would obtain more clinically relevant behavioral effects of PD by testing it in this
model. PolyI:C 4.0 mg/kg was dissolved in 0.9% saline. This dose of PolyI:C was chosen
based on previous studies using the same dose and route of administration to generate
schizophrenia-like phenotypes (Piontkewitz et al, 2009, 2012; Wolff and Bilkey, 2008,
2010; Yee et al, 2012; Zuckerman and Weiner, 2005; Zuckerman et al, 2003). Prenatal
PolyI:C treatment was performed on G13-15, when pregnant dams were anesthetized with
3% isoflurane (Fisher Scientific, Denver, CO) in 98% O2 and given a single iv injection at
the tail vein. Siblings of pups born from these mothers and not used in the current study
displayed abnormally low maternal separation-induced pup ultrasonic vocalizations (USVs,
unpublished observation), indicating that these MIA animals do exhibit schizophrenia-like
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phenotypes. For all experiments, rats were assigned such that the MIA and control offspring
were distributed across each drug testing condition, and offspring from the same litter were
assigned to different groups to minimize litter effects as a confound (Zorrilla, 1997). Table 1
summarizes the experimental groups and treatment conditions in each experiment.
Subjects were housed two per cage upon weaning (postnatal day [P] 21), in 182 × 50 ×
188.1cm transparent polysulfone individually ventilated cages under 12h light/dark
conditions (light on between 0630 and 1830 h). Room temperature was maintained at 22 ±
1°C with a relative humidity of 45–60%. Food and water was available ad libitum. Animals
remained in their home cages until the time of the experiments (~P 75–95). All experiments
were run during the light cycle. All procedures were approved by the Institutional Animal
Care and Use Committee at the University of Nebraska-Lincoln.
Drugs and choice of doses

NIH-PA Author Manuscript

PD (Sigma-Aldrich, St. Louis, MO) was dissolved in 0.9% saline. Three doses of PD were
tested: 1.0, 4.0 and 8.0mg/kg (subcutaneous [sc]). These doses of PD were chosen based on
previous studies related to systemic injections of PD in CAR, PPI and hyperlocomotion tests
(Feifel et al, 1999, 2003, 2004, 2007, 2008, 2010, 2011; Holly et al, 2011; Shilling and
Feifel, 2008; Shilling et al, 2004). CLZ (5.0 mg/kg, sc) was dissolved in distilled sterile
water with 1.0–1.5% glacial acetic acid. The dose of CLZ acutely inhibits CAR, PCPinduced disruption of PPI, and PCP-induced hyperlocomotion based on our previous work
(Feng et al, 2013; Li et al, 2004, 2007, 2009, 2010a; Mead and Li, 2010; Sun et al, 2009;
Zhang and Li, 2012). The injection solution of PCP (gift from National Institute on Drug
Abuse Chemical Synthesis and Drug Supply Program) was obtained by mixing the drug
with 0.9% saline. The doses of PCP (3.2 mg/kg for experiment 2; 1.5 mg/kg for experiment
3, sc) were chosen based on our previous work (Feng et al, 2013; Li et al, 2012a; Sun et al,
2009; Zhang and Li, 2012; Zhao and Li, 2010). These doses of PCP are shown to induce
robust hyperlocomotion and disruptions in PPI without causing severe stereotypy (Gleason
and Shannon, 1997; Kalinichev et al, 2008, 2009). All drugs were administrated at 1.0
ml/kg.
Two-way avoidance conditioning apparatus

NIH-PA Author Manuscript

Eight identical two-way shuttle boxes custom designed and manufactured by Med
Associates (St. Albans, VT) were used. Each box was housed in a ventilated, soundinsulated isolation cubicle (96.52 cm W × 35.56 cm D × 63.5 cm H). Each box was 64 cm
long, 30 cm high (from grid floor), and 24 cm wide, and was divided into two equal-sized
compartments by a partition with an arch style doorway (15 cm high × 9 cm wide at base). A
barrier (4 cm high) was placed between the two compartments, so the rats had to jump from
one compartment to the other. The grid floor consisted of 40 stainless-steel rods with a
diameter of 0.48 cm, spaced 1.6 cm apart center to center, through which a scrambled
footshock (unconditioned stimulus [US], 0.8mA, maximum duration: 5 s) was delivered by a
constant current shock generator (Model ENV-410B) and scrambler (Model ENV-412). The
rat location and crossings between compartments were monitored by a set of 16 photobeams
(ENV-256-8P) affixed at the bottom of the box (3.5 cm above the grid floor). Illumination
was provided by two houselights mounted at the top of each compartment. The conditioned
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stimulus (CS, i.e. 76 dB white noise) was produced by a speaker (ENV 224 AMX) mounted
on the ceiling of the cubicle, centered above the shuttle box. Background noise
(approximately 74 dB) was provided by a ventilation fan affixed at the top corner of each
isolation cubicle. All training and testing procedures were controlled by Med Associates
programs running on a computer. In each CAR box, an USV microphone (P 48/Emkay
Microphone, Avisoft Bioacoustics, Berlin, Germany) was mounted on the ceiling of the twocompartment chamber. The microphone was connected via an E-MU 0404 USB Audio
device to a computer. Acoustic data were displayed in real time by the Avisoft
RECORDER, a multi-channel triggering hard-disk recording software (version 3.4; Avisoft
Bioacoustics), and were recorded at a sampling rate of 192 kHz in 16 bit format and
analyzed by Avisoft SASLab Pro (version 4.51; Avisoft Bioacoustics).
Prepulse inhibition of acoustic startle reflex apparatus

NIH-PA Author Manuscript

The PPI test was performed using six Startle Monitor Systems (Kinder Scientific, Julian,
CA). Each system, controlled by a PC, was housed in a compact sound attenuation cabinet
(36 cm wide × 28 cm deep × 50 cm high). A speaker (diameter: 11 cm) mounted on the
cabinet’s ceiling was used to generate acoustic stimuli (70 dB–120 dB). The startle response
was measured by a piezoelectric sensing platform on the floor, which was calibrated daily.
During testing, rats were placed in a rectangular box made of transparent Plexiglas (19 cm
wide × 9.8 cm deep × 14.6 high) with an adjustable ceiling positioned atop the box,
providing only limited restraint while prohibiting ambulation.
Locomotor activity monitoring apparatus
This apparatus has been described before (Feng et al, 2013; Sun et al, 2009; Zhao and Li,
2010). Sixteen activity boxes were housed in a quiet room. The boxes were 48.3 cm × 26.7
cm × 20.3 cm transparent polycarbonate cages, each equipped with a row of 6 photocell
beams (7.8 cm between two adjacent photobeams) placed 3.2 cm above the floor of the
cage. A computer with recording software (Aero Apparatus Sixbeam Locomotor System
v1.4) was used to detect the disruption of the photocell beams and recorded the number of
beam breaks.
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Experiment 1: Assessment of PD149163 tolerance using the conditioned avoidance
response test
This experiment examined whether repeated PD treatment could induce a tolerance effect in
adult female rats in the CAR model as previously found with CLZ in adult male rats (Feng
et al, 2013; Li et al, 2010a; Qiao et al, 2013a). It consisted of four phases: avoidance
training, repeated PD testing, PD challenge test and CLZ challenge test.
Avoidance training—35 rats (~P 75) were first habituated to the CAR boxes for 2 days
(30 min/day) and then trained for conditioned avoidance responding for 10 consecutive
days/sessions. Each session consisted of 30 trials. Every trial started by presenting a white
noise (CS) for 10 s, followed by a continuous scrambled foot shock (0.8 mA, US, maximum
duration = 5 s) on the grid floor. If a subject moved from one compartment into the other
within the 10 s of CS presentation, it avoided the shock and this shuttling response was
recorded as avoidance. If the rat remained in the same compartment for more than 10s and
Pharmacol Biochem Behav. Author manuscript; available in PMC 2016 January 01.
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made a crossing upon receiving the footshock, this response was considered as escape. If the
rat did not respond during the entire 5 s presentation of the shock, the trial was terminated
and escape failure was recorded. The total number of avoidance responses was recorded for
each session. Intertrial intervals varied randomly between 30 and 60 s.

NIH-PA Author Manuscript

Repeated PD testing—At the end of the training session (~P 87), rats were assigned to
one of four groups: VEH (0.9% saline, n = 9), PD 1.0 mg/kg (PD 1.0, n = 9), PD 4.0 mg/kg
(PD 4.0, n = 9), and PD 8.0 mg/kg (PD 8.0, n=8) and tested daily for avoidance response for
5 consecutive days. The CS-only (no shock, 30 trials/daily session) condition was used to
eliminate any relearning effect caused by the presence of the US. During each drug test, rats
were first injected with PD or VEH. Thirty min later, they were placed in the CAR boxes
and tested. USV at the 22 kHz range (20–32 kHz) – an established assay for fear and anxiety
(Mead et al, 2008; Sun et al, 2010a) – were also recorded for the first 10 min of the testing
using Avisoft Recorder software (Version 3.4). Settings included sampling rate at 192 kHz,
format 16 bit. For acoustical analysis, recordings were transferred to Avisoft SASLab Pro
(Version 4.51) and a fast Fourier transformation (FFT) was conducted. Spectrograms were
generated with an FFT-length of 256 points and a time window overlap of 50% (100%
Frame, FlatTop window). The spectrogram was produced at a frequency resolution of 750
Hz and a time resolution of 0.6667 ms. Call detection was provided by an automatic single
threshold-based algorithm (threshold: −20 dB) and a hold-time mechanism (hold time: 0.02
s).
PD challenge test—One day after the last drug test day, all rats were retrained drug-free
for one day under the CS-only (no shock) (~P 92) condition and one day under the CS-US
condition (~P 93) to ensure all groups had a comparable level of avoidance responding
before the tolerance assessment. PD tolerance was assessed 1 day later (~P 94), when all rats
were injected with a challenge dose of PD 1.0 mg/kg and tested for avoidance performance,
22 kHz USV and intertrial crossing in the CS-only condition (30 trials) 30min later. This
procedure of using a lower challenge dose of the same drug has been successfully used in
our previous studies with many APDs (Feng et al, 2013; Li et al, 2010a, 2012b; Qiao et al,
2013a; Sparkman and Li, 2012; Swalve and Li, 2012; Zhang and Li, 2012). It also avoided
the floor effect (i.e. a high dose may cause a maximal avoidance disruption, leaving no room
to show a sensitization or tolerance effect).
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CLZ challenge test—After the PD challenge test, all rats were once again retrained for 2
drug-free sessions, the first under the CS-only condition and the second under the CS-US
condition, then challenged with CLZ 5.0 mg/kg 1 day later, when they were injected with
CLZ and tested 1 h later for avoidance performance in the CS-only condition (30 trials).
Experiment 2: Assessment of PD149163 tolerance using the phencyclidine-induced
hyperlocomotion test
This experiment examined whether repeated PD treatment could induce a tolerance effect in
adult female rats in PCP-induced hyperlocomotion. It consisted of three phases: repeated
PD testing, PD challenge test and CLZ challenge test.
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Repeated PD testing—Forty six rats were first habituated to the locomotor activity
apparatus for 2 days (~ P95, 30min/day). Following habituation rats were assigned to one of
six groups: VEH+VEH (n=7), PCP+VEH (n=8), PD 1.0+PCP (n=8), PD 4.0+PCP (n=8), PD
8.0+PCP (n=8), or VEH+PD 4.0 (n=7), and tested daily for locomotor activity for 5
consecutive days. During each session, rats were first injected with PD or VEH and
immediately placed in the boxes for 30 min. At the end of the 30 min period, they were
taken out and injected with PCP 3.2 mg/kg or VEH and placed back in the boxes for another
60 min. Locomotor activity (number of photobeam breaks) was measured in 5min intervals
throughout the entire 90-min testing session.
PD challenge test—Two days after the last drug test day, all rats were rehabituated to the
locomotor activity boxes (~ P103, 30 min) and PD tolerance was assessed 1 day later (~
P104), when all rats were injected with both PD 1.0 mg/kg and PCP 3.2 mg/kg and tested
for locomotor activity.

NIH-PA Author Manuscript

CLZ challenge test—After the PD challenge test, all rats were once again rehabituated to
the locomotor activity boxes then challenged with CLZ 5.0 mg/kg + PCP 3.2 mg/kg 1 day
later.
Experiment 3: Assessment of PD149163 tolerance using the phencyclidine-induced
disruptions of prepulse inhibition test
This experiment examined whether repeated PD treatment induces a tolerance effect in adult
female rats in PCP-induced disruption of PPI. It consisted of three phases: repeated PD
testing, PD challenge test and CLZ challenge test.

NIH-PA Author Manuscript

Repeated PD testing—Forty six rats were first habituated to the prepulse inhibition
apparatus for 2 days (~ P75, 10min). Following habituation rats were assigned to one of five
groups: VEH+VEH (n=10), PCP+VEH (n=9), PD 1.0+PCP (n=9), PD 4.0+PCP (n=9), or
PD 8.0+PCP (n=9), and tested daily for PPI for 3 consecutive days. During each session,
rats were first injected with PD or VEH, followed 20 min later with an injection of PCP 1.5
mg/kg or VEH, then placed in the PPI boxes and tested 10 min later. PPI test procedures
were adapted from Culm and Hammer (2004). The PPI session lasted approximately 18 min
and began with a 5 min period of 70 dB background noise (which continued throughout the
duration of the session) followed by four different trial types: PULSE ALONE trials and
three types of PREPULSE+PULSE trials, which consisted of a 20 ms 73, 76, or 82 dB
prepulse (3, 6, and 12 dB above background) followed 100 ms later by a 120 dB pulse. Each
session was divided into 4 blocks. Blocks 1 and 4 were identical, each consisting of 4
PULSE ALONE trials. Blocks 2 and 3 were also identical and each consisted of 8 PULSE
ALONE trials and 5 of each PREPULSE+PULSE trial type. A total of 54 trials were
presented during each test session. Trials within each block were presented in a
pseudorandom order and were separated by a variable intertrial interval averaging 15 s
(ranging from 9 to 21 s). Startle magnitude was defined as the maximum force (measured in
Newtons) applied by the rat to the startle apparatus recorded over a period of 100 ms
beginning at the onset of the pulse stimulus. Between each stimulus trial, 100 ms of activity
was recorded when no stimulus was present. These trials were called NOSTIM trials and
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were not included in the calculation of intertrial intervals. Responses recorded during
NOSTIM trials are considered a measure of gross motor activity within the PPI boxes.
Startle responses from testing blocks 2 and 3 were used to calculate percent prepulse
inhibition (%PPI) for each acoustic prepulse trial type:

PD challenge test—Two days after the last drug test day, all rats were rehabituated to the
PPI apparatus (~P81) and PD tolerance was assessed 1 day later (~ P82), when all rats were
injected with both the intermediate dose of PD 4.0 mg/kg and PCP 1.5 mg/kg and tested for
PPI. Due to animal illness, only 9 rats were used for the VEH+VEH group during the PD
+PCP challenge.

NIH-PA Author Manuscript

CLZ challenge test—After the PD challenge test, all rats were once again rehabituated to
the PPI chambers (~P 84) then challenged with CLZ 5.0 mg/kg 1 day later, when they were
injected first with CLZ, followed 50 min later with PCP 1.5 mg/kg, and tested 10min later
for PPI. Due to procedural errors, only data from 8 rats in the VEH+VEH group were used
for the CLZ challenge.
Statistical analysis

NIH-PA Author Manuscript

All data are expressed as mean ± SEM. In the case where no group differences were found
between control and MIA animals, the data are combined. Avoidance data in experiment 1
and motor activity data in experiment 2 from the five drug test sessions were analyzed using
a factorial repeated measures analysis of variance (ANOVA) with the between-subjects
factor being drug group and the within-subjects factor being test day, followed by post hoc
LSD tests. Data from the predrug and challenge test days were analyzed by one-way
ANOVA followed by post hoc LSD tests. As there was no significant interaction between
the three prepulse intensities and PD treatment, percent PPI data for the three drug days in
experiment 3 were reported as the average of the three prepulse intensities (e.g. 73, 76 and
82 dB). The magnitude of the acoustic startle reflex (ASR) was calculated as the average
response on the PULSE ALONE trials, excluding the first and last block of 4 PULSE
ALONE trials. The general activity was calculated as the average response on the NOSTIM
trials. Percent PPI, ASR and activity data from the drug test period were first analyzed using
repeated measures ANOVAs with the drug treatment group as a between subjects factor and
test day as a within-subjects factor, followed by post hoc LSD tests. For all analyses, p<0.05
was considered statistically significant.

RESULTS
Experiment 1: Assessment of PD149163 tolerance using the conditioned avoidance
response test
Avoidance training and repeated PD testing—Figure 1a shows the percentage of
avoidance responses on the last training (predrug) day and the five drug test days. There was
no group difference on the last training day. Throughout the drug test phase, PD treatment
Pharmacol Biochem Behav. Author manuscript; available in PMC 2016 January 01.
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consistently disrupted avoidance response. Repeated measures ANOVA revealed a main
effect of group, F(3,31)=144.654, p<0.001 and a significant group × day interaction,
F(12,90)=2.655, p=0.004. Post hoc LSD tests revealed that the three PD groups all made
significantly less avoidances than the VEH group, all p<0.001, although they did not differ
significantly from each other.
22 kHz USV—Figure 1b shows the number of 22 kHz USVs on the last training (predrug)
day and the five drug test days. There was no group difference on the last training day.
Throughout the drug test phase, PD treatment persistently suppressed the number of 22 kHz
USVs. Repeated measures ANOVA revealed a main effect of group, F(3,30)=9.244,
p<0.001. Post hoc LSD tests revealed that the three PD groups all emitted significantly less
vocalizations than the VEH group, all p<0.001, although they did not differ significantly
from each other.
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PD challenge test—Figure 1c shows the percentage of avoidance responses on the
second retraining (predrug) day and the PD tolerance challenge day. There was no group
difference on the predrug day. When all rats were given PD 1.0 mg/kg on the challenge day,
one-way ANOVA revealed a significant effect of group, F(3,30)=7.011, p=0.001. Post hoc
LSD tests showed that the PD 4.0 and 8.0 groups made significantly more avoidances than
the VEH group, p=0.005 and p<0.001, respectively. The PD 8.0 group also showed
significantly higher levels of avoidance than the PD 1.0 group, p=0.005. No significant
group difference was detected on the number of 22 kHz USVs on the predrug or challenge
day.
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CLZ challenge test—Figure 1d shows the percentage of avoidance responses on the
predrug day and the CLZ challenge test day. Before the CLZ challenge, there was no
significant group difference. On the challenge day when all rats were given CLZ 5.0 mg/kg,
one-way ANOVA revealed a significant effect of group, F(3,27) = 4.365, p=0.012. Post hoc
LSD tests showed that the PD 4.0 and 8.0 groups made significantly fewer avoidances than
the VEH group, p=0.003 and 0.004, respectively, as well as fewer avoidances than the PD
1.0 group, p=0.036 and 0.042, respectively. Statistical analysis also revealed a significant
effect of prenatal treatment, F(1,27)=6.195, p=0.019, as well as a significant group ×
prenatal treatment interaction, F(3,27)=3.890, p=0.020 (figure 1e). Post hoc LSD analysis
showed that prenatally immune activated animals previously exposed to VEH or PD 1.0
showed significantly higher numbers of avoidances compared to the non-prenatally
challenge animals that were also exposed to VEH and PD, p=0.001 and 0.043, respectively.
No significant group difference was detected on the number of 22 kHz USVs on the predrug
or challenge day.
Experiment 2: Assessment of PD149163 tolerance using the phencyclidine-induced
hyperlocomotion test
Repeated PD test: 30 min before PCP—Figure 2a shows the mean locomotor activity
during the 30-min test period after the PD or VEH injection throughout the five days of drug
testing. Repeated measures ANOVA revealed a main effect of group, F(5,40)=24.952,
p<0.001 and day, F(4,37)=5.652, p=0.001, and a significant group × day interaction, F(20,
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160)=2.701, p<0.001. Post hoc LSD tests showed that, except on day 1, the PCP+VEH
group has significantly lower locomotor activity than the VEH+VEH group, p=0.007. The
PD 1.0, 4.0, and 8.0+PCP groups also showed significantly lower activities than the PCP
+VEH group, all p<0.001. Additionally, except on day 1, the VEH+PD 4.0 group showed
significantly higher levels of activity than the PD 1.0 and 4.0+PCP groups, both p<0.01.
Repeated PD test: 60 min after PCP—Figure 2b shows the mean locomotor activity
during the 60-min test period after the PCP or VEH injection throughout the five days of
drug testing. Repeated measures ANOVA revealed a main effect of group, F(5,40)=17.506,
p<0.001 and day, F(4,37)=6.788, p<0.001. Post hoc LSD tests showed that the PCP+VEH
group had significantly higher locomotor activities than all other groups, all p<0.001, while
the PD 4.0+VEH group showed significantly lower levels of activity than the VEH+VEH
group, p=0.016.
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PD challenge test—Figure 2c shows the mean locomotor activity during the
rehabituation (predrug) and PD challenge test day. One-way ANOVA revealed a significant
main effect of group during the predrug day, F(5,40)=6.193, p<0.001. Post hoc LSD tests
showed that the PD 1.0, 4.0 and 8.0+PCP groups all displayed significantly lower levels of
activity than the VEH+VEH group, all p<0.002. The PD 1.0 and 8.0+PCP groups also
showed significantly lower activity levels than the PCP+VEH group, p=0.013 and 0.007,
respectively. There was no significant difference between groups throughout the duration of
the challenge test, when all groups were given PCP and PD 1.0 mg/kg.
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CLZ challenge test—Figure 2d shows the mean locomotor activity during the
rehabituation (predrug) and CLZ challenge test day. One-way ANOVA revealed a
significant main effect of group only for the 60-min test period after the PCP or VEH
injection, F(5,40)=2.644, p=0.037. Post hoc LSD test for the 60-min test period on the CLZ
challenge test day showed that the PD 1.0 and 4.0+PCP groups showed significantly
suppressed activities compared to the VEH+VEH group, p=0.020 and 0.028, respectively.
The VEH+PD 4.0 group also saw a significantly lower level of locomotor activity than both
the VEH+VEH and PCP+VEH groups, p=0.006 and 0.019, respectively. There was no
significant difference between the groups for the predrug day or the 30-min test period after
the CLZ 5.0 mg/kg or VEH injection during the CLZ challenge test day. There was also no
significant difference between prenatal treatments across all phases of the PCP-induced
hyperlocomotion testing.
Experiment 3: Assessment of PD149163 tolerance using the phencyclidine-induced
disruptions of prepulse inhibition test
Repeated PD testing: PPI—Figures 3a shows the percentage of PPI on the three drug
test days. Statistical analysis revealed a main effect of day, F(2,40)=3.308. p=0.047, and a
main effect of group, F(4,41)=14.092, p<0.001. Post hoc LSD tests showed that the PD 1.0,
4.0 and 8.0+PCP groups all displayed higher PPI than the VEH+VEH and the PCP+VEH
groups, p=0.002 for PD 1.0+PCP and p<0.001 for 4.0 and 8.0. While we observed a
significantly lower PPI in the PCP+VEH group compared to VEH+VEH on the first day of
PCP administration (multivariate ANOVA of PCP × PD: F(4,45)=9.044, p<0.001, post hoc
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LSD of VEH+VEH versus PCP+VEH, p=0.033), this effect was abolished following the
second and third day of PCP administration.
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Repeated PD testing: ASR—Figure 3b shows the startle magnitudes on the three drug
test days. Repeated measures ANOVA revealed a main effect of group, F(4,41)=7.788,
p<0.001 and day, F(2,40)=3.343, p=0.045. Post hoc LSD tests showed that the PD 1.0, 4.0,
and 8.0+PCP groups all had significantly lower startle responses than the PCP+VEH group,
all p=0.001. PD 4.0 and 8.0+PCP groups also showed significantly lower startles than the
VEH+VEH group, p=0.012 and 0.003, respectively.
Repeated PD testing: General motor activity—Figure 3c shows the general motor
activity recorded during the NOSTIM trials on the three drug test days. Repeated measures
ANOVA revealed a main effect of group, F(4,41)=5.064, p=0.002 and a significant group ×
day interaction, F(8,82)=2.629, p=0.013. Post hoc LSD tests showed that the PD 4.0 and
8.0+PCP groups had significantly lower activity than the VEH+VEH and PCP+VEH
groups, p<0.01 for all groups.
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PD challenge test—Figure 4a shows the PPI percentage on the rehabituation (predrug)
and PD challenge test day. There was no significant difference in PPI or ASR on the predrug
day. However, one-way ANOVA of general motor activity on the predrug day revealed a
main effect of group, F(4,35)=4.176, p=0.007 (figure 4b). Post hoc LSD tests showed that
the PD 4.0 and 8.0+PCP groups generated significantly lower magnitudes than the VEH
+VEH group, p=0.005 and 0.001, respectively, and additionally the PD 8.0+PCP group’s
general motor activity was significantly lower than the PCP+VEH group as well, p=0.030.
No significant difference was found between the groups in PPI, ASR or general motor
activity on the PD challenge day, when all rats were given PD 4.0+PCP.
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CLZ challenge test—Figure 4c shows the percentage of PPI on the rehabituation
(predrug) and CLZ challenge test day. There was no significant difference in PPI or ASR on
the predrug day. However, one-way ANOVA of general motor activity during the predrug
day again showed a main effect of group, F(4,34)=2.882, p=0.037 (figure 4d). Post hoc LSD
tests showed that the PD 8.0+PCP group displayed significantly reduced general motor
activity compared to the VEH+VEH, PCP+VEH, and PD 1.0+PCP groups, p=0.010, 0.011,
and 0.013, respectively. No significant difference was found between the groups in PPI,
ASR or general motor activity on the CLZ challenge day, when all rats were given CLZ 5.0
mg/kg+PCP. There was no significant difference between prenatal treatments across all
phases of the PCP-induced PPI deficits testing.

DISCUSSION
This study investigated the acute and chronic effects of the NT analogue PD149163 (PD)
using three validated preclinical assays of antipsychotic (APD) efficacy, conditioned
avoidance response (CAR), phencyclidine (PCP)-induced hyperlocomotion, and PCPinduced disruptions in prepulse inhibition (PPI). PD (Lys(CH2NH)Lys-Pro-Trp-tLe-LeuOET) is a NT analogue selective for the NTS1 receptor (Petrie et al, 2004) with structural
modifications that makes it less prone to enzymatic degradations when injected peripherally
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(Banks et al, 1995). Using the two-phase paradigm that our group has established for
assessing APD sensitization and tolerance (i.e. increased and decreased behavioral response
to a drug due to past drug exposure), we confirmed the tolerance effect of PD in the CAR
test in the higher doses tested, and saw APD-like effects in other well established tests
without tolerance development over days of treatment. The discrepancy among different
tests suggested that differences in sensitivities for assessing effects of chronic APD
treatments exist across different behavioral measurements.
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In accordance with previous studies on NT receptor activation using both central (Norman et
al, 2008a) and systemic (Feifel et al, 2003; Shilling et al, 2003) administrations, our results
showed that acute PD treatment at three different doses (1.0, 4.0, and 8.0 mg/kg) were able
to inhibit CAR, reverse the PPI disruptions produced by PCP, and suppress PCP-induced
hyperlocomotion. These acute effects were most likely due to central mechanisms of NT
receptor activation after peripheral injection. As the inhibition of CAR by APDs has been
suggested to be mediated by blockade of dopamine (DA) D2 receptors in the
mesocorticolimbic DA pathway (Wadenberg and Hicks, 1999), the therapeutic mechanism
of NT receptor stimulation might be related to its close association with the mesolimbic DA
system (Binder et al, 2001). NTS1 is found to co-localize with DA D2 receptors, and
activation of these receptors on DAergic neurons in the ventral tegmental area (VTA) has
been shown to increase DAergic neuronal activity (Mercuri et al, 1993; Nalivaiko et al,
1998; Wu and Wang, 1995). In addition, NT in the prefrontal cortex (PFC) can also increase
VTA DAergic neuronal activity (Fatigati et al, 2000; Rompré et al, 1998), and peripheral
NT can enhance DA efflux in both the nucleus accumbens and the medial PFC (mPFC),
similar to atypical APDs (Prus et al, 2007). Furthermore, it has been suggested that the
mechanism of PCP-induced hyperactivity involves increased DA output in the mesolimbic
area as well as a rise in extracellular DA concentration in the mPFC, and systemic pretreatment of animals with the NT analogue NT69L prevented the DA increase (Li et al,
2010b).
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Previous work only reports PD’s tolerance effect in the induction phase (the repeated drug
testing phase) in which PD gradually loses its ability to inhibit CAR. In the present study,
we were able to demonstrate it in the expression phase, when the previously drug treated
groups were compared directly with the vehicle (VEH) control group. This finding provided
a better and cleaner demonstration of tolerance as it was supported by a between-group
comparison – that the PD groups and VEH group were not different on the predrug days, but
only showed differences under the PD challenge. We showed PD 4.0 and 8.0 mg/kg were
able to induce a partial tolerance effect in the CAR model. After five days of PD treatment,
the effect of PD in the challenge test using the lowest dose of PD (1.0 mg/kg) tested during
the repeated drug days was severely reduced, resulting in a high level of avoidance response
in rats previously exposed to PD compared to drug naïve rats. It is important to note that
many previous studies investigating PD saw APD-like effects in doses lower than 1.0
mg/kg, suggesting the higher doses of 4.0 and 8.0 mg/kg may have activated other non-NT
systems within the brain. However, since there is no guidance currently on the clinically
relevant doses of PD, our dosing choices were based on previous work by Holly et al, 2011
showing that while doses below 1.0 mg/kg were able to rescue drug-induced PPI deficits in
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other literature, PD was unable to induce acute CAR disruption at doses below 1.0 mg/kg,
and even at 8.0 mg/kg was only able to produce a 60% disruption of CAR.
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Our present result of PD tolerance in CAR is similar to our previous work showing that prior
repeated clozapine (CLZ) administration causes a decreased response to the APD in a
challenge test compared to control (Feng et al, 2013; Li et al, 2011; Qiao et al, 2013a). It
also agrees with results using another NT analogue, NT69L, by Hertel et al, 2002, although
in that study tolerance was assessed at only one time point, at the end of twice daily
treatments for seven days. Using our unique CS-only test procedure allowed us to identify
true avoidance responses that are not contaminated by US-induced learning that might occur
throughout the test sessions. This paradigm allowed us to note that with both CLZ and PD,
there was no gradual development of tolerance throughout the five repeated test days in
CAR under the drug condition. Instead, tolerance was only expressed during the challenge
test after two days of CAR retraining under the drug free condition. The mechanism of this
phenomenon possibly involves the down-regulation of NTS1 receptors. Cell and tissue
culture studies have shown that NT receptor stimulation with agonists causes receptor
desensitization and internalization (Hermans et al, 1997; Vanisberg et al, 1991), as well as a
decrease in cyclic GMP formation (Gilbert et al, 1988; Hermans et al, 1996), although no
studies have looked at the time course of receptor down-regulation in vivo. It is thus possible
that a time-dependent delay of onset accompanies the development of this behavioral
tolerance.
PD has also been implicated as a potential anxiolytic (Shilling and Feifel, 2008), hence we
also compared the 22 kHz ultrasonic vocalizations (USVs) – a measure of negative affect
(Brudzynski and Chiu, 1995; Tonoue et al, 1986) – in CAR. Although repeated PD
treatment reduced 22 kHz USVs, no tolerance was seen during challenge. These results
contradicted those by Prus et al, 2013, where repeated PD administration decreased the
number of conditioned footshock-induced 22 kHz USVs. Since the mentioned study
administered PD 1.0 mg/kg for ten consecutive days, it is possible that the discrepancy is
due to the longer time period required for tolerance to develop in 22 kHz USV-related
behaviors.

NIH-PA Author Manuscript

The drug-induced hyperlocomotion model has been extensively used in reporting the
chronic effects of NT receptor activation (Boules et al, 2003; Feifel et al, 2008; Hertel et al,
2001; Meisenberg and Simmons, 1985; Norman et al, 2008a; Rompré, 1997). Using our
previously established model (Feng et al, 2013; Li et al, 2011; Qin et al, 2013; Sun et al,
2009, 2010b; Zhang and Li, 2012; Zhao et al, 2012), after five days of repeated combined
administration of PD and PCP, we saw no tolerance in the subsequent challenge test, as low
dose PD (1.0 mg/kg) challenge resulted in the same level of PCP hyperlocomotion reduction
between drug naïve animals and those with prior PD exposure at all doses. However, we did
see a decrease in spontaneous locomotor activity under the drug free condition for groups
that received repeated PD treatment in conjuction with PCP, suggesting that the drug
treatment did induce lasting behavioral changes that persisted in the drug free system. In
terms of PD’s tolerance phenomenon in the drug-induced hyperactivity model, discrepancies
exist among current literature. This could largely be attributed to variations in experimental
designs. For example, repeated intracerebroventricular (ICV) NT infusions for four and 21
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days sensitized rats to amphetamine-induced hyperactivity using an amphetamine-only
challenge (Rompré, 1997), while ICV PD infusions for seven days exhibited tolerance under
the amphetamine-only challenge, with the acute PD attenuation of amphetamine-induced
hyperlocomotion abolished after seven days of PD infusion (Norman et al, 2008b). Other
studies saw tolerance development in NT agonism’s suppression of spontaneous motor
activity (Meisenberg and Simmons, 1985). Finally, Boules et al, 2003 and Feifel et al, 2008
both concluded no change in behavioral sensitivity using the two commonly studied NT
analogues, NT69L and PD, respectively. Our model included daily testing of PD’s
suppression of PCP-induced hyperlocomotion, which more accurately captured the time
course of the drug effect. In addition, most of the previous studies only tested one dose of
the drug, while here we compared three different doses and saw no dose-dependent
response.
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In the hyperlocomotion experiment, it is also important to note that while the PD4+VEH
group exhibited low baseline locomotion, suggesting a sedating effect of this dose of PD, it
is indisputable that general sedating effects can occur with any drugs suggested to induce
APD-like effects, especially atypical drugs such as CLZ and olanzapine (OLZ). Our
previous work showed that the sedative effect of an APD drug could not account for its
avoidance disruptive effect. In our CAR experiment, we saw a general decrease in intertrial
crossing (a measurement of gross motor activity) under the influence of currently
established APDs (Qiao et al. 2013). However, this does not imply a lack of APD efficacy.
Therefore, while the sedating effect of PD may exist, we do not believe that it diminished
the significance of the results presented here. In our opinion, the sedative effect and putative
APD effect of PD all contributed to its avoidance disruptive effect, and both effects may
undergo a tolerance development with different time courses. Future research is needed to
tease out their individual contributions in various behavioral tests.
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Unlike CAR and PCP-induced hyperlocomotion, as a preclinical model of APD efficacy and
schizophrenia pathology, few studies have utilized PPI to capture the time course effects of
APD actions. Feifel et al, 2007 have attempted to evaluate the tolerance development of PD
using PPI and found that 16 days of continuous PD 1.0 mg/kg administration in the naturally
PPI-deficient Brattleboro rats resulted in the same level of PPI enhancement as the first day
of PD treatment, indicating a lack of tolerance or sensitization over time. However, as the
study only examined the drug’s effect on PPI at the beginning and end of the treatment
period, it was unable to assess the changes that might have occurred throughout the
treatment duration. In our experiment, we gave daily injections of PD at three different
doses (1.0, 4.0, and 8.0 mg/kg), and tested the animals’ PPI each day. Although our results
also saw an absence of development over days in PPI, similar to our hyperlocomotion
results, we again saw a decrease in the gross motor activity under the drug free condition for
groups that received repeated PD treatment in conjunction with PCP. The results from drug
free days in the PPI and hyperlocomotion experiments pointed to the likelihood that this
long lasting change requires the combined action of PD with PCP. In support of this result,
previous NT agonism studies have shown that there is a possible dose dissociation amongst
various behaviors (Feifel et al, 1997; Prus et al, 2007), and the optimal effective dose may
differ between behaviors.
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Our group has previously investigated the phenomenon of sensitization cross-transfer (Li et
al, 2007; Mead and Li, 2010; Qiao et al, 2013b). In a recent study on the repeated treatment
effects of the atypical APD asenapine (ASE) (Qin et al, 2013), our group evaluated whether
sensitization induced by ASE could be transferred to other atypical APDs such as OLZ and
CLZ. We showed that the behavioral sensitization induced by ASE did in fact transfer to a
subsequent OLZ challenge. Similarly, here we saw a transfer of the tolerance induced by PD
in CAR in a subsequent CLZ challenge. In addition to our previous work showing CLZ to be
the only atypical APD that produces a tolerance effect in our repeated CAR assessment
paradigm (Feng et al, 2013; Qiao et al, 2013a, 2013b; Zhao et al, 2012), the results here of
PD’s tolerance in CAR and its tolerance cross-transferring to CLZ suggest the possibility
that the therapeutic mechanisms of PD might be similar to those of the atypical APD CLZ. It
is also interesting to note that while no tolerance was seen in the PD challenge for PCPinduced hyperlocomotion, the subsequent CLZ challenge actually showed an increased
sensitivity to CLZ in groups previously repeatedly treated with PD and PCP. Though the
reason for this finding is currently unclear, it adds strength to the idea that PD and CLZ
might share unique similarities, and supports the notion that NTS1 receptor agonists might
be therapeutically efficacious due to the production of similar behavioral response as CLZ in
a preclinical test of high predictive validity for APD efficacy.
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In addition to assessing the repeated effects of PD using three distinct preclinical models, we
also examined the generalizability of our findings by including both wild type animals and
prenatally immune activated ones. Maternal immune activation (MIA) is widely accepted as
a preclinical model for the neuroinflammatory theory of schizophrenia (Piontkewitz et al,
2009; Zuckerman and Weiner, 2005). In this study, we saw no difference in repeated PD
treatments between the MIA and control animals. However, we did see some differences
within the CLZ challenges. The cause for this observation is uncertain, but conceivably
involves differences in receptor levels. Various work regarding MIA animals have
implicated DA dysfunction as a possible cause of phenotypic abnormalities (Meyer et al,
2010; Vuillermot et al, 2010; Zuckerman and Weiner, 2003). For example, Zuckerman, et.
al. showed that prenatally immune activated animals displayed increased sensitivity in the
amphetamine-induced hyperlocomotion test and increased striatal DA release, while Ozawa
et al, 2006 found increased striatal DA metabolites, 3,4-dihydroxyphenylacetic acid and
homovanillic acid, in MIA animals using high-performance liquid chromatography. It seems
likely that while APDs may still alter baseline functions in these animals as seen in the
current work, the DAergic disruption results in differences of drug effects on this population
relative to controls.
It is possible that our choices of experimental parameters produced results that are different
compared to other previous work. Our choice of using female subjects provided novel
findings of PD’s APD-like effects in females. However, this also limited the ability for
comparison with previous work in male rats. For example, previous studies have shown that
there are significant sex differences in behavioral response to MK-801, an NMDA
antagonists with similar behavioral disruptions to PCP (Zhao et al. 2013), and human studies
have clearly shown a sex difference in PPI response (Aasen et al. 2005). Thus, the use of
female subjects, inclusion of both control and prenatally immune activated animals, choice
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of dosage, numbers of test days, and challenge dose might have all contributed to
differences in our study. Regardless, in summary, the findings we present here provide novel
observations of PD’s tolerance properties and contribute data to the increasing body of
knowledge supporting NT receptor agonists as possible novel APDs.
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1.

The NTS1 receptor agonist PD149163 produces tolerance in CAR in adult
female rats.

2.

PD149163 tolerance cross-transfers to clozapine challenge in CAR.

3.

PD149163 acutely attenuates PCP-induced hyperlocomotion but shows no
tolerance.

4.

PD149163 acutely rescues PCP-induced PPI deficits in but shows no tolerance.
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Figure 1.

Assessment of PD149163 (PD) tolerance in conditioned avoidance response: (a) The
percentage of avoidance responses and (b) 22kHz ultrasonic vocalizations made by rats from
vehicle (VEH), PD 1.0, 4.0, and 8.0 mg/kg groups on the last training day (predrug) and
throughout the five drug test days. *p<0.01 relative to the VEH group. (c) The percentage of
avoidance responses made by rats on the retraining day (predrug) and the PD tolerance
assessment day. *p<0.01 relative to the VEH group; #p<0.01 relative to the PD 1.0 group.
(d) The percentage of avoidance responses made by rats on the second retraining day
(predrug) and the clozapine (CLZ) tolerance assessment day. *p<0.01 relative to the VEH
group; #p<0.05 relative to the PD 1.0 group. (e) Effects of prenatal treatment on CLZ
tolerance. Percentage avoidance responses made by rats from the two prenatal treatment
groups. *p<0.01 for the prenatally immune-activated group relative to control in the VEH
condition and #p<0.05 in the PD 1.0 condition. All values are expressed as mean + SEM.
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Figure 2.
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Assessment of PD149163 (PD) tolerance using phencyclidine-induced hyperlocomotion: (a)
Mean locomotor activity during the 30-min test period after the PD or vehicle (VEH)
injection and (b) the 60-min test period after the phencyclidine (PCP) or VEH injection
made by rats from the VEH+VEH, PCP+VEH, PCP+PD 1.0, PCP+PD 4.0, PCP+PD 8.0,
and VEH+PD 4.0 groups throughout the five drug test days. *p<0.01 relative to the PCP
+VEH group; &p<0.01 relative to the PD 1.0+PCP and PD 4.0+PCP groups; **p<0.01
relative to all groups; #p<0.05 relative to the VEH+VEH group. (c) Mean locomotor activity
during the rehabituation day (predrug), 30-min test period after the PD or VEH injection,
and 60-min test period after the PCP or VEH injection made by rats on the PD tolerance
assessment day and (d) clozapine tolerance assessment day are expressed as mean + SEM.
*p<0.01 relative to the VEH+VEH group; #p<0.05 relative to the PCP+PD1.0 and PCP
+PD8.0 groups; &p<0.05 relative to the VEH+VEH group. All values are expressed as mean
+ SEM.

Pharmacol Biochem Behav. Author manuscript; available in PMC 2016 January 01.

Chou et al.

Page 26

NIH-PA Author Manuscript
NIH-PA Author Manuscript
Figure 3.

NIH-PA Author Manuscript

Repeated PD149163 (PD) administration in phencyclidine (PCP)-induced disruption of
prepulse inhibition (PPI): (a) Percentage of PPI, (b) startle magnitude in Newtons, and (c)
general motor activity in Newtons made by rats from the vehicle (VEH)+VEH, PCP+ VEH,
PCP+PD 1.0, PCP+PD 4.0, and PCP+PD 8.0 groups throughout the three drug test days are
expressed as mean + SEM. #p<0.01 relative to both the VEH+VEH and PCP+VEH groups;
*p<0.05 relative to the VEH+VEH group alone; &p<0.01 relative to the PCP+VEH group
alone.
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Assessment of PD149163 (PD) tolerance in phencyclidine (PCP)-induced disruption of
prepulse inhibition (PPI): (a) Percentage of PPI during the rehabituation day (predrug) and
the PD tolerance assessment. (b) General motor activities in Newtons during the
rehabituation day prior to the PD tolerance assessment. **p<0.01 relative to the VEH+VEH
group; #p<0.05 relative to the PCP+VEH group. (c) Percentage of PPI during the
rehabituation day (predrug) and the clozapine (CLZ) tolerance assessment day. (d) General
motor activities in Newtons during the rehabituation day prior to the CLZ tolerance
assessment. #p<0.05 relative to the VEH+VEH, PCP+VEH, and PCP+PD 1.0 groups. All
values are expressed as mean + SEM.
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